AlzeCure Pharma AB (DE:AC6)
FRANKFURT:AC6
AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.07 - €0.57
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€53.79M
Enterprise Value€125.61M
Total Cash (Recent Filing)€50.34M
Total Debt (Recent Filing)€5.12M
Price to Earnings (P/E)―
Beta-1.00
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding137,897,340
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Modest DebtA low absolute debt load and debt-to-equity ~0.16 give the company financial flexibility common to early-stage biotechs. With limited interest burden the firm can prioritize R&D spend or licensing discussions without near-term solvency pressure, supporting multi-quarter program execution.
Focused CNS R&D PlatformA concentrated R&D focus on CNS disorders, including Alzheimer’s and pain, aligns the company with structurally growing therapeutic demand and enables domain expertise. A platform approach to small-molecule discovery can create multiple licensable assets, improving long-term partnerability.
Lean Operating StructureA very small headcount indicates a lean cost base and operational agility, reducing fixed overhead relative to larger peers. For an R&D-stage biotech this supports capital efficiency, allowing funds to be directed primarily to trials or partnering activities over multiple funding rounds.
Bears Say
No Revenue; Persistent Net LossesThe absence of product revenue combined with recurring sizable net losses means the company lacks internally generated, sustainable funding. Continued losses erode equity and make the business dependent on external financing or timely licensing deals to support ongoing R&D programs.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow indicate ongoing cash burn tied to development activities. This creates a structural reliance on external capital, which can force dilutive financings or constrain the timing and scale of clinical programs absent material partnering or non-dilutive funding.
Material Equity Erosion Over TimeMarked decline in shareholders' equity over several years reflects cumulative losses and reduces the balance-sheet cushion. Lower equity weakens borrowing capacity, increases vulnerability to adverse outcomes, and raises the probability that management will need to seek dilutive capital to sustain operations.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.57 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €53.79M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 72 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 137,897,340 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.024%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ) is a pharmaceutical firm focused on pioneering drug treatments for debilitating conditions impacting the central nervous system (CNS). The company's pipeline of potential medicines is rooted in three distinct research platforms: NeuroRestore, Alzstatin, and Painless. Among its experimental compounds, ACD856 is currently in Phase I clinical trials for multiple indications, including Alzheimer's disease, sleep disturbances, traumatic brain injuries, and Parkinson's disease. Furthermore, ACD857, ACD679, and ACD680 are being developed for Alzheimer's treatment. Another candidate, ACD440, a TRPV1 antagonist intended for neuropathic pain, has successfully completed its Phase I clinical assessment. Additionally, TrkA-NAM is in development to alleviate osteoarthritic pain. Founded in 2012, AlzeCure Pharma AB (publ) maintains its headquarters in Huddinge, Sweden.